Member Info for Laura2022

Just filter Joe/tradingstar

He's a waste of effort

Eg inthedark account

Member since 2013

3 pages of posts, last ones on housebuilder TW 5 yrs ago and now appears on MET1

Mmmmm

Filtered

Same as last week

Ignore them and instead do want Tomhh, i and others did and buy low and be in good profit

Let's see if we can finally break the 65p level, still going well from the 40p low

Mark Davies

1d

We shall be in Boston next week for BIO International #BIO2025! Hayley Close will be there to provide guidance on how at Physiomics plc we use modelling and simulation #MIDD to support our clients from preclinical into clinical development for optimal dosing and design.

You've been very positive on ICON 2022/23

Surely you should look in the mirror? Rather than blame those like myself that called it well from all.time lows post suspension and consolidation?

Lanks

Posted in: ICON

Posts: 259

Price: 0.0055

No Opinion

RE: This week…20 Feb 2023 09:49

I agree Fitzy. This is a top appointment. He is not going to come onboard merely as a figurehead.

Look at his back story...

Mr. Blouin has 25 years of investment and banking experience. He was a senior banker with Morgan Stanley, JP Morgan and BNP Paribas, during which he was involved in over €50 billion of capital markets, corporate finance and property transactions across Europe.

Massive companies. Now he’s with us. I’m getting more interested again.

Those buying at any point since April 2025 have called it better than those over the preceding 4yrs ?

4yrs posting on ICON..no wonder you're bitter

Name change and ticker

DCR

Dead,Crocked Resources

The emergence of in silico modelling is transforming the landscape of drug development.

With the FDA's recent announcement to phase out mandatory animal testing, approaches such as model-informed drug development (MIDD) and computational simulations are at the forefront of this transformation – enabling researchers to simulate complex human systems with tremendous accuracy. 🐁

At Physiomics plc, we’ve seen firsthand how MIDD and PK/PD modelling can optimise drug development from preclinical research to clinical success. As highlighted in the article, integrating these advanced computational tools into the regulatory process is no longer a novelty - it’s becoming an essential foundation for decision-making. We recently wrote a blog discussing how MIDD can help sponsors optimise dosing strategies, which you can read here: https://lnkd.in/euXDtUmP

The future of drug development will be data-driven, with in silico research at the forefront. It’s exciting to see how this paradigm shift is unfolding and how it can help drive more efficient, effective and patient-centric treatments. 🚀

#drugdevelopment #biotech #pharma #insilico #MIDD #fda #animaltesting #improvingoutcomes #pyc

https://lnkd.in/eDGMS3_U

Jvip

Good to see you, PYC looks ready too

Good afternoon 86

Yes, and now can sell over 175,000 at 2.9p but only buy 75,000 before NT

Charts bottomed

Make that c £1500 now, then NT

Jvip

Interesting developments son ICON...see 86KB comments

£250k marker cap could be £2mln+

Davey50 not posted for a month

Left or banned?

Buy limits slashed to about £2000,

86kb

That's for that, that sounds exciting

Have you purchase any ICON ?

Real spread 2.75p to 3 1p

HAYD is up 150% in 2 days after a positive trading update yesterday

Bmcm

See the RNS rhwy out when they returned from suspended